All AbMole products are for research use only, cannot be used for human consumption.
In vitro: Treatment of caspase-1 (interleukin-1 [IL-1] converting enzyme [ICE]) with Ossirene (AS101) inhibits its enzymatic activity in a dose-dependent manner. Moreover, AS101 treatment causes a significant reduction in the active form of IL-18 and IL-1 in peripheral blood mononuclear cells (PBMC) and in human HaCat keratinocytes. The inhibitory effect of AS101 does not involve nitric oxide (NO) or interferon- (IFN- ), two possible regulators of IL-18 production, and does not occur at the mRNA level. It may exert effects through a posttranscriptional mechanism. AS101 induced SIRT1 expression in a dose dependent manner in three different cell lines, HEK293, HL-60 and Rin-5f. Incubation of HEK293 and HL-60 cell lines with AS101 (0.1-2.5μg/ml) resulted in a dose dependent reduction in PPARγ protein expression relative to the control cells, and the reduction of PPARγ expression is in parallel to increased SIRT1 expression.
In vivo: Ossirene (AS101) downregulates IL-18 and IL-1 serum levels in a mouse model of lipopolysaccharide (LPS)-induced sepsis, resulting in increased survival. It has also been shown to be protective against lethal and sublethal effects of irradiation and chemotherapy. In a model of cecal ligation and puncture (CLP)-induced sepsis in mice, AS101 also exerted beneficial effects. AS101 treated rats showed a large increase in SIRT1 protein levels in the liver and kidney extracts of rats treated with AS101. AS101 prevents development of insulin resistance in vivo. AS101 affects SIRT1 related metabolic pathways by changing the insulin levels. AS101 treatment prevents hyperglycemia associated with T2D(type 2 diabetes) and some of the symptoms of the disease in the HFD(high fat diet)+STZ(Streptozotocin) rat model.
Int J Antimicrob Agents. 2024 Aug 05.
Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo
Ossirene purchased from AbMole
Infect Drug Resist. 2021 Aug 13;14:3135-3143.
Increased Expression of IL-10 in Peripheral Blood Mononuclear Cells Correlates with Negative Interferon-γ Release Assay Results in Culture-Confirmed Tuberculosis Patients
Ossirene purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | Human peripheral blood mononuclear cells (PBMC) |
| Preparation method | In vitro, PBMCs were first treated with various concentrations of AS101, and after 1 h SAC (10-3 v/v) was added. After 24 h, supernatants were collected and evaluated for cytokine content. |
| Concentrations | 0.01, 0.05, 0.5, 1, 1.5, 2 μg/mL |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | c57BL/6J and BALB/c mice |
| Formulation | PBS |
| Dosages | 10 μg/mouse |
| Administration | i.p. |
| Molecular Weight | 312.05 |
| Formula | C2H4Cl3O2Te.H4N |
| CAS Number | 106566-58-9 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage | -20°C, dry, sealed |
| Related IL Receptor/Related Products |
|---|
| IL-15-IN-1
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. |
| IL-17 modulator 3
IL-17 modulator 3 is an IL-17 modulator. |
| IL-17 modulator 4
IL-17 modulator 4 is a proagent of IL-17 modulator 1. |
| IL-17A modulator-3
IL-17A modulator-3 is a IL-17A modulator. |
| IL-17 modulator 4 sulfate
IL-17 modulator 4 sulfate is a proagent of IL-17 modulator 1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
